Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.

Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.

Item
http://www.wikidata.org/entity/Q45014139
Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.Cost-utility analyses of drug therapies in breast cancer: a systematic review.Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancerTime-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer.Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.Efficacy of the CMFVP regimen in patients with metastatic breast cancer previously treated with anthracycline and taxane.Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
P2860

Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.

Item
http://www.wikidata.org/entity/Q45014139
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
@en
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
@nl
type
label
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
@en
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
@nl
prefLabel
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
@en
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P356
P1433
P1476
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698